Current Report Filing (8-k)
September 05 2019 - 2:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): August 30, 2019
CO-DIAGNOSTICS,
INC.
(Exact
name of small business issuer as specified in its charter)
Utah
|
|
1-38148
|
|
46-2609363
|
(State
or other jurisdiction
of incorporation or organization)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
2401
S. Foothill Drive, Suite D, Salt Lake City, Utah 84109
(Address
of principal executive offices)
(801)
438-1036
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
CODX
|
|
NASDAQ
Capital Market
|
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07. Submission of Matters to a Vote of Security Holders
Co-Diagnostics,
Inc. (the “Company”) held its Annual Meeting on August 30, 2019 at its principal executive offices. According to the
inspector of elections, the stockholders present in person or by proxy represented 11,677,730 shares of common stock (entitled
to one vote per share) which was equal to 68.2% of the shares of common stock entitled to vote. At the Annual Meeting, the stockholders
voted on the following two proposals and cast their votes as follows:
Proposal
1: Election of Directors.
Director
|
|
Votes For
|
|
|
Votes Withheld
|
|
|
Broker Non-Votes
|
|
Dwight H. Egan
|
|
|
7,576,981
|
|
|
|
35,383
|
|
|
|
3,743,684
|
|
Eugene Durenard
|
|
|
7,577,281
|
|
|
|
35,083
|
|
|
|
3,743,684
|
|
Edward L. Murphy
|
|
|
7,577,534
|
|
|
|
34,830
|
|
|
|
3,743,684
|
|
Richard S. Serbin
|
|
|
7,578,281
|
|
|
|
34,083
|
|
|
|
3,743,684
|
|
James Nelson
|
|
|
7,071,160
|
|
|
|
541,204
|
|
|
|
3,743,684
|
|
Each
of the individuals listed above was elected as a director of the Company to serve until the 2020 annual meeting of stockholders
and until successors are duly elected or until the earliest of their removal or resignation.
Proposal
2: Ratification of the appointment of Haynie & Company as the Company’s independent registered public accounting firm
for the fiscal year ending December 31, 2019.
Votes For
|
|
Votes Against
|
|
|
Votes Abstain
|
|
11,402,369
|
|
|
129,312
|
|
|
|
146,049
|
|
The
stockholders voted to ratify the selection of Haynie & Company as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2019.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
|
CO-DIAGNOSTICS,
INC.
|
|
|
|
|
By:
|
/s/
Dwight H. Egan
|
|
Name:
|
Dwight
H. Egan
|
|
Title:
|
Chief
Executive Officer
|
Date:
September 5, 2019
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024